| Literature DB >> 30371169 |
Richard P Sloan1,2, Peter A Shapiro3, Paula S McKinley1, Matthew Bartels4, Daichi Shimbo5, Vincenzo Lauriola1, Wahida Karmally6, Martina Pavlicova7, C Jean Choi2, Tse-Hwei Choo2, Jennifer M Scodes2, Pamela Flood8, Kevin J Tracey9.
Abstract
Background Consensus panels regularly recommend aerobic exercise for its health-promoting properties, due in part to presumed anti-inflammatory effects, but many studies show no such effect, possibly related to study differences in participants, interventions, inflammatory markers, and statistical approaches. This variability makes an unequivocal determination of the anti-inflammatory effects of aerobic training elusive. Methods and Results We conducted a randomized controlled trial of 12 weeks of aerobic exercise training or a wait list control condition followed by 4 weeks of sedentary deconditioning on lipopolysaccharide (0, 0.1, and 1.0 ng/mL)-inducible tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and on toll-like receptor 4 in 119 healthy, sedentary young adults. Aerobic capacity by cardiopulmonary exercise testing was measured at study entry (T1) and after training (T2) and deconditioning (T3). Despite a 15% increase in maximal oxygen consumption, there were no changes in inflammatory markers. Additional analyses revealed a differential longitudinal aerobic exercise training effect by lipopolysaccharide level in inducible TNF -α ( P=0.08) and IL-6 ( P=0.011), showing T1 to T2 increases rather than decreases in inducible (lipopolysaccharide 0.1, 1.0 versus 0.0 ng/mL) TNF- α (51% increase, P=0.041) and IL-6 (42% increase, P=0.11), and significant T2 to T3 decreases in inducible TNF- α (54% decrease, P=0.007) and IL-6 (55% decrease, P<0.001). There were no significant changes in either group at the 0.0 ng/mL lipopolysaccharide level for TNF- α or IL-6. Conclusions The failure to support the primary hypotheses and the unexpected post hoc findings of an exercise-training-induced proinflammatory response raise questions about whether and under what conditions exercise training has anti-inflammatory effects. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01335737.Entities:
Keywords: clinical trial; exercise training; inflammation
Mesh:
Substances:
Year: 2018 PMID: 30371169 PMCID: PMC6201415 DOI: 10.1161/JAHA.118.010201
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1CONSORT diagram.
Figure 2Western blots of TLR4 from a participant with T1, T2, and T3 blood draws. A representative Western blot of peripheral blood mononuclear cell lysates probed with monoclonal antibodies against TLR4 and ß‐actin. 20 μg of cell lysates were loaded on the gel in duplicates (columns 2, 3, for T1; columns 4, 5 for T2, and columns 6, 7 for T3). Ctl indicates HEL293 cell lysate with TLR4 serving as positive control; MW, molecular weight marker. The arrows in the left margin indicate the TLR4 and ß‐actin proteins detected. MWs are listed on the right.
Demographic and T1 Characteristics of the Participants Randomized to Exercise and Wait‐List Group (N=119)
| Wait List (n=59) | Aerobic Training (n=60) | |||
|---|---|---|---|---|
| N | Mean (SD) or n (%) | N | Mean (SD) or n (%) | |
| Age, y | 59 | 31.4 (6.2) | 60 | 31.2 (5.7) |
| Sex | 59 | 60 | ||
| Male | 28 (47.5%) | 28 (46.7%) | ||
| Female | 31 (52.5%) | 32 (53.3%) | ||
| BMI, kg/m2 | 59 | 24.9 (3.8) | 59 | 24.9 (3.8) |
| Body fat % | 56 | 25.0 (9.5) | 58 | 25.9 (9.7) |
| AMED index | 57 | 4.4 (1.7) | 60 | 4.3 (1.8) |
| Race | 59 | 60 | ||
| Asian | 18 (30.5%) | 15 (25.0%) | ||
| Native Hawaiian or Pacific Islander | 0 (0.0%) | 1 (1.7%) | ||
| Black or African American | 11 (18.6%) | 10 (16.7%) | ||
| White | 20 (33.9%) | 20 (33.3%) | ||
| Other | 10 (16.9%) | 14 (23.3%) | ||
| Ethnicity | 59 | 60 | ||
| Hispanic | 12 (20.3%) | 19 (31.7%) | ||
| Not Hispanic | 47 (79.7%) | 41 (68.3%) | ||
AMED indicates alternative Mediterranean diet; BMI, body mass index.
Summary of Observed Descriptive Summaries of ITT Sample and Adjusted Model Results of Fitness Measures and Inflammation Markers (N=119)
| Measure | Wait‐List Group Mean (SD) or Median (IQR) | Aerobic Training Group Mean (SD) or Median (IQR) | ||||
|---|---|---|---|---|---|---|
| T1 | T2 (12 Weeks) | T3 (16 Weeks) | T1 | T2 (12 Weeks) | T3 (16 Weeks) | |
| VO2max | 31.00 (6.4) | 30.11 (6.2) | 29.38 (6.5) | 30.39 (6.9) | 34.74 (8.4) | 33.28 (8.3) |
| Fat‐free mass | 118.81 (25.3) | 115.60 (23.5) | 117.16 (24.1) | 113.48 (22.1) | 117.08 (23.3) | 117.84 (24.0) |
| Inducible TNF‐α | ||||||
| Lipopolysaccharide 0.0 ng/mL | 11.61 (5.4–25.0) | 10.68 (5.0–22.5) | 11.99 (6.4–19.1) | 11.77 (7.7–19.3) | 11.20 (6.87–23.1) | 14.83 (7.0–33.4) |
| Lipopolysaccharide 0.1 ng/mL | 142.55 (36.7–364.2) | 101.79 (33.8–350.0) | 85.70 (22.6–323.1) | 109.25 (25.7–354.1) | 131.86 (33.7–506.3) | 113.69 (18.0–289.6) |
| Lipopolysaccharide 1.0 ng/mL | 434.02 (142.8–1105.5) | 501.91 (117.6–872.9) | 449.9 (80.6–1076.2) | 607.13 (84.8–1453.2) | 681.54 (247.6–1604.6) | 432.09 (141.7–1056.3) |
| Inducible interleukin‐6 | ||||||
| Lipopolysaccharide 0.0 ng/mL | 4.53 (2.6–8.3) | 3.96 (2.5–14.0) | 4.16 (2.7–6.9) | 5.73 (3.5–10.0) | 5.49 (4.3–9.5) | 6.11 (3.7–20.3) |
| Lipopolysaccharide 0.1 ng/mL | 248.93 (44.7–484.7) | 211.90 (63.7–445.2) | 219.63 (22.6–605.5) | 236.66 (21.6–548.7) | 245.21 (101.1–649.9) | 151.99 (10.1–408.5) |
| Lipopolysaccharide 1.0 ng/mL | 586.87 (122.8–1456.0) | 600.97 (132.6–1485.0) | 572.27 (151.1–1351.3) | 799.28 (226.1–1498.8) | 866.58 (358.5–1466.3) | 414.59 (138.5–1281.7) |
| TLR4 | 0.50 (0.3–0.9) | 0.46 (0.2–0.7) | 0.43 (0.2–0.8) | 0.41 (0.2–0.9) | 0.38 (0.2–0.6) | 0.37 (0.2–0.7) |
IQR indicates interquartile range; ITT, intent‐to‐treat; TLR4, toll‐like receptor 4; TNF‐α, tumor necrosis factor‐α; VO2max, maximal oxygen consumption.
Values significantly different between groups at the equivalent time point in the adjusted model (P<0.001).
Values significantly different between T1 and particular time in the same group in the adjusted model (P<0.05). In per‐protocol analyses, this is no longer significant for the wait‐list group (P>0.05).
Values significantly different between T1 and particular time in the same group in the adjusted model (P<0.001).
Values significantly different between T1 and particular time in the same group in the per‐protocol adjusted and unadjusted models (P<0.05).
Median and IQR are presented for outcomes that had skewed distribution and were log‐transformed in the analyses.
Values significantly different between groups at the equivalent time point in the adjusted model (P<0.05).
Figure 3Observed T1 mean plotted with adjusted model estimated T2 and T3 means and standard errors of VO 2max on the intent‐to‐treat (ITT) sample.
Figure 4Observed T1 mean plotted with adjusted model estimated T2 and T3 means and standard errors of fat‐free mass (lbs) on ITT sample.
Figure 5Observed T1 geometric mean plotted with adjusted model estimated T2 and T3 geometric means and standard errors of inducible TNF‐α at lipopolysaccharide (A) 0.0 ng/mL, (B) 0.1 ng/mL, and (C) 1.0 ng/mL; and inducible interleukin‐6 at lipopolysaccharide (D) 0.0 ng/mL, (E) 0.1 ng/mL, and (F) 1.0 ng/mL. All figures were based on the ITT sample.